Deeper Dive: Understanding DarioHealth Corp (DRIO) Through its Various Ratios

For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.

The price of DarioHealth Corp (NASDAQ: DRIO) closed at $0.55 in the last session, down -12.81% from day before closing price of $0.63. In other words, the price has decreased by -$12.81 from its previous closing price. On the day, 0.72 million shares were traded. DRIO stock price reached its highest trading level at $0.64 during the session, while it also had its lowest trading level at $0.52.

Ratios:

We take a closer look at DRIO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.77 and its Current Ratio is at 2.01. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.27.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, TD Cowen on January 29, 2025, Downgraded its rating to Hold and sets its target price to $1 from $2 previously.

On May 13, 2022, Alliance Global Partners Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $8.75.

On April 22, 2021, Cowen started tracking the stock assigning a Outperform rating and target price of $31.Cowen initiated its Outperform rating on April 22, 2021, with a $31 target price.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 12 ’24 when Nelson Steven Charles bought 5,000 shares for $0.91 per share. The transaction valued at 4,546 led to the insider holds 55,000 shares of the business.

Nelson Steven Charles bought 5,000 shares of DRIO for $4,221 on Sep 10 ’24. The Chief Commercial Officer now owns 45,000 shares after completing the transaction at $0.84 per share. On Sep 11 ’24, another insider, Nelson Steven Charles, who serves as the Chief Commercial Officer of the company, bought 5,000 shares for $0.80 each. As a result, the insider paid 4,022 and bolstered with 50,000 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DRIO now has a Market Capitalization of 24232772 and an Enterprise Value of 26435436. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.86 while its Price-to-Book (P/B) ratio in mrq is 0.32. Its current Enterprise Value per Revenue stands at 0.943 whereas that against EBITDA is -0.641.

Stock Price History:

The Beta on a monthly basis for DRIO is 1.24, which has changed by -0.4953704 over the last 52 weeks, in comparison to a change of 0.15366066 over the same period for the S&P500. Over the past 52 weeks, DRIO has reached a high of $1.55, while it has fallen to a 52-week low of $0.50. The 50-Day Moving Average of the stock is -21.39%, while the 200-Day Moving Average is calculated to be -26.42%.

Shares Statistics:

According to the various share statistics, DRIO traded on average about 154.96K shares per day over the past 3-months and 231170 shares per day over the past 10 days. A total of 42.71M shares are outstanding, with a floating share count of 34.96M. Insiders hold about 21.37% of the company’s shares, while institutions hold 16.71% stake in the company. Shares short for DRIO as of 1752537600 were 2962362 with a Short Ratio of 19.12, compared to 1749772800 on 2960947. Therefore, it implies a Short% of Shares Outstanding of 2962362 and a Short% of Float of 7.33.

Dividends & Splits

Against a Trailing Annual Dividend Yield of 0.0

Earnings Estimates

The current rating of DarioHealth Corp (DRIO) is the result of assessments by 3.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.03 and low estimates of -$0.11.

Analysts are recommending an EPS of between -$0.21 and -$0.43 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is $0.04, with 3.0 analysts recommending between $0.33 and -$0.21.

Revenue Estimates

According to 3 analysts, the current quarter’s revenue is expected to be $6.91M. It ranges from a high estimate of $7M to a low estimate of $6.8M. As of the current estimate, DarioHealth Corp’s year-ago sales were $6.25MFor the next quarter, 3 analysts are estimating revenue of $8.54M. There is a high estimate of $10M for the next quarter, whereas the lowest estimate is $7.04M.

A total of 4 analysts have provided revenue estimates for DRIO’s current fiscal year. The highest revenue estimate was $35.85M, while the lowest revenue estimate was $28.63M, resulting in an average revenue estimate of $32.14M. In the same quarter a year ago, actual revenue was $27.04MBased on 3 analysts’ estimates, the company’s revenue will be $37.67M in the next fiscal year. The high estimate is $38.92M and the low estimate is $36.11M.

Leave a Reply

Your email address will not be published. Required fields are marked *

DWinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.